Lipopeptide vaccines - Yesterday, today, and tomorrow

Lancet Infectious Diseases

Volumn 2, Issue 7, 2002, Pages 425-431

  BenMohamed, Lbachir ^a   Wechsler, Steven L ^a   Nesburn, Anthony B ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPEPTIDE; VACCINE;

CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; DRUG SYNTHESIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0036295173     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00318-3     Document Type: Review

References (67)

1. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
2. Vaccine development for hepatitis C
3. Can the immune response control HIV infection?
4. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
5. Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations
6. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits
7. HIV infection and immunization
8. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
9. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers
10. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules
11. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper; and cytotoxic T lymphocytes responses against a malaria liver stage antigen in mice and chimpanzees
12. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CDS(+) T lymphocyte activation
13. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses
14. Simian immunodeficiency virus as a model for vaccination against HIV: Induction in rhesus macaques of GAG- and NEF specific cytotoxic T lymphocytes by lipopeptides
15. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
16. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein
17. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multi-restricted lipopeptides
18. Efficiency of peptide and lipopeptide for in vivo priming of virus-specific cytotoxic T cells
19. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals
20. Lipopeptide particles as the immunologically active component of CTL inducing vaccines
21. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection-induction of a primary cytotoxic T lymphocyte response in humans
22. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens
23. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants
24. Adjuvants for human vaccines - Current status, problems and future prospects
25. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1
26. Attenuated mutants of the intracellular bacterium Listeria monocytogenes obtained by single amino acid substitutions in listeriolysin O
27. Liposomes as carriers for vaccines
28. Immunological adjuvants: A role for liposomes
29. Antigenic presentation of small molecules and peptides conjugated to a preformed ISCOM as carrier
30. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigen peptide system
31. Immunogenicity of a synthetic HBsAg peptide: Enhancement by conjugation to a fatty acid carrier
32. Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D
33. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide
34. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help
35. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopepide vaccine
36. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide
37. Influence of peptide acylation, liposome incorporation, synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: Implications for subunit vaccines
38. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
39. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide
40. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations
41. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types
42. Synthetic peptides coupled to the lipotripeptide P3CSS induce in vivo B T-helper cell responses to HIV-1 reverse transcriptase
43. Rapid alterations in the plasma membrane structure of macrophages stimulated with bacterial lipopeptides
44. Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells
45. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant
46. Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells
47. Dendritic cells and the control of immunity
48. Oral vaccination with immune stimulating complexes
49. IFN-gamma-derived lipopeptides: Influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells
50. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: Importance of spacer amino acids
51. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: Role of N-terminal hydrophobic portion in its multiple functions
52. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2
53. Discrimination of bacterial lipoproteins by Toll-like receptor 6
54. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis
55. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
56. Induction of CTL responses and identification of a novel epitope of hepatitis B virus surface antigens in C57BL/6 mice immunized with recombinant vaccinia viruses
57. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class 1 processing and presentation in vitro
58. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine
59. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses
60. From sporozoite to liver stages: The saga of the irradiated sporozoite vaccine
61. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: Dependence on HLA class II restricted T(H) response
62. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme
63. Immunobiology of dendritic cells in the respiratory tract: Steady-state and inflammatory sentinels?
64. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: Selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue
65. The dendritic cell system and its role in immunogenicity
66. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells